Following the exciting 2022 in-person Communiqué Awards, we are pleased to offer our readers a selection of case studies that ...

A lot has changed for the better over the past few years. As Mike Dixon, the author of this issue’s foreword, writes: “There has been a renewed and reinvigorated focus on diversity, equity and ...

PMEA returned on 21 November at the Sheraton Grand in London to recognise excellence within pharmaceutical marketing. The ...

Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...

Communicating complex medical information has the potential to overwhelm patients and caregivers. The key is blending ...

Patient recruitment and retention company, Innovative Trials, was shortlisted as a finalist in the PME Award for its ...

In 2022, there is a renewed focus on diversity, equity and inclusion (DE&I) in the workplace. But for DE&I to be successful, ...

What makes a story powerful? Storytelling is becoming more critical than ever. In medical publications, healthcare providers ...

UCB’s Bimzelx (bimekizumab-bkzx) has been approved by the US Food and Drug Administration (FDA) to treat active moderate-to-severe hidradenitis suppurativa (HS) in adults. Estimated to affect one in ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been recommended by the European Medicines Agency’s human medicines ...

New Environmental, Social and Governance (ESG) regulations coming into force across the EU in 2025 stand to shift how ...